Nurix stock: H.C. Wainwright raises target for Nurix stock to USD 36.00

Published on 10/23/2026 at 04:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter revenue reached USD 673.1 million on August 31, 2026. The USD 1.1 billion cash balance gives context to Nurix stock.

Third-quarter financial picture

H.C. Wainwright raised its target from USD 34.00 to USD 36.00 on October 16, 2026.
Nurix reported USD 673.1 million in third-quarter revenue on October 12, 2026.
Cash, cash equivalents and marketable securities totaled USD 1.1 billion on August 31, 2026.

NRIX, US67080M1036, Illustration mit AI erstellt.

Nurix Therapeutics (ISIN US67080M1036) received a USD 36.00 price target from H.C. Wainwright, up from USD 34.00 on October 16, 2026, according to Investing.com. The move followed Nurix's fiscal third-quarter results and keeps the analyst view above the latest reported Nasdaq reference of USD 25.51 on October 22, 2026.

Analyst target follows Roche deal

H.C. Wainwright maintained a Buy rating while lifting its target from USD 34.00 to USD 36.00. The firm cited Nurix's fiscal third-quarter results, which included USD 673.1 million in collaboration and license revenue and USD 4.73 in diluted earnings per share, according to Investing.com.

What drove the revenue figure?

The answer was collaboration income rather than product sales. Nurix said USD 653.2 million came from license revenue tied to its Roche collaboration, while a Sanofi development milestone contributed USD 10.0 million, according to AP News. Net income reached USD 549.8 million for the three months ended August 31, 2026, compared with a USD 86.4 million net loss in the year-earlier quarter.

Three milestones set the sequence

On September 29, 2026, Nurix announced a USD 7.0 million milestone under its Pfizer collaboration. On October 5, 2026, the company agreed with Gilead Sciences to extend an oncology research program and receive a USD 10.0 million fee. On October 12, 2026, Nurix reported USD 673.1 million in third-quarter revenue and USD 549.8 million in net income, according to AP News.

Reported dates shape the next view

The latest reporting date was October 12, 2026, while the reported quarter ended August 31, 2026. Those dates frame the financial comparison and the clinical progress described in the update.

Cash supports clinical expansion

Cash, cash equivalents and marketable securities totaled USD 1.1 billion on August 31, 2026, after Nurix received a USD 700 million Roche upfront payment. The company said this balance extends its cash runway into the second half of 2029, according to AP News. The financing cushion gives the Phase 3 DAYBreak CLL-306 trial and other pipeline programs more time to generate clinical evidence.